REFERENCE
[1] Anon WHO recommends new name for monkeypox disease
[2] WHO 2022 Monkeypox
[3] Magnus P von, Andersen E K, Petersen K B and Birch-Andersen A
2009 A POX-LIKE DISEASE IN CYNOMOLGUS MONKEYS Acta Pathologica
Microbiologica Scandinavica 46 156–76
[4] Ladnyj I D, Ziegler P and Kima E 1972 A human infection caused
by monkeypox virus in Basankusu Territory, Democratic Republic of the
Congo Bull World Health Organ 46 593–7
[5] Nolen L D, Osadebe L, Katomba J, Likofata J, Mukadi D, Monroe B,
Doty J, Hughes C M, Kabamba J, Malekani J, Bomponda P L, Lokota J I,
Balilo M P, Likafi T, Lushima R S, Ilunga B K, Nkawa F, Pukuta E,
Karhemere S, Tamfum J-J M, Nguete B, Wemakoy E O, McCollum A M and
Reynolds M G 2016 Extended Human-to-Human Transmission during a
Monkeypox Outbreak in the Democratic Republic of the Congo Emerg Infect
Dis 22 1014–21
[6] Anon 1984 The current status of human monkeypox: Memorandum from
a WHO Meeting Bull World Health Organ 62 703–13
[7] Kumar N, Acharya A, Gendelman H E and Byrareddy S N 2022 The
2022 outbreak and the pathobiology of the monkeypox virus J Autoimmun
131 102855
[8] WHO 2022 WHO Director-General’s statement at the press
conference following IHR Emergency Committee regarding the multi-country
outbreak of monkeypox - 23 July 2022
[9] Anon 2022-23 Mpox (Monkeypox) Outbreak: Global Trends
[10] Cho C T and Wenner H A 1973 Monkeypox virus. Bacteriol Rev 37
1–18
[11] Anon 130s.pdf
[12] Kugelman J R, Johnston S C, Mulembakani P M, Kisalu N, Lee M S,
Koroleva G, McCarthy S E, Gestole M C, Wolfe N D, Fair J N, Schneider B
S, Wright L L, Huggins J, Whitehouse C A, Wemakoy E O, Muyembe-Tamfum J
J, Hensley L E, Palacios G F and Rimoin A W 2014 Genomic Variability of
Monkeypox Virus among Humans, Democratic Republic of the Congo Emerg
Infect Dis 20 232–9
[13] Smith G L and Law M 2004 The exit of vaccinia virus from
infected cells Virus Res 106 189–97
[14] Moss B 2001 Poxviridae: the viruses and their replication, vol.
2 Knipe, DMl
[15] Berthet N, Descorps-Declère S, Besombes C, Curaudeau M, Nkili
Meyong A A, Selekon B, Labouba I, Gonofio E C, Ouilibona R S, Simo
Tchetgna H D, Feher M, Fontanet A, Kazanji M, Manuguerra J-C, Hassanin
A, Gessain A and Nakoune E 2021 Genomic history of human monkey pox
infections in the Central African Republic between 2001 and 2018 Sci Rep
11 13085
[16] Shchelkunov S N, Totmenin A V, Safronov P F, Mikheev M V,
Gutorov V V, Ryazankina O I, Petrov N A, Babkin I V, Uvarova E A,
Sandakhchiev L S, Sisler J R, Esposito J J, Damon I K, Jahrling P B and
Moss B 2002 Analysis of the Monkeypox Virus Genome Virology 297 172–94
[17] Esposito J J and Knight J C 1985 Orthopoxvirus DNA: a
comparison of restriction profiles and maps Virology 143 230–51
[18] Likos A M, Sammons S A, Olson V A, Frace A M, Li Y,
Olsen-Rasmussen M, Davidson W, Galloway R, Khristova M L, Reynolds M G,
Zhao H, Carroll D S, Curns A, Formenty P, Esposito J J, Regnery R L and
Damon I K Y 2005 A tale of two clades: monkeypox viruses Journal of
General Virology 86 2661–72
[19] Happi C, Adetifa I, Mbala P, Njouom R, Nakoune E, Happi A,
Ndodo N, Ayansola O, Mboowa G, Bedford T, Neher R A, Roemer C, Hodcroft
E, Tegally H, O’Toole Á, Rambaut A, Pybus O, Kraemer M U G, Wilkinson E,
Isidro J, Borges V, Pinto M, Gomes J P, Freitas L, Resende P C, Lee R T
C, Maurer-Stroh S, Baxter C, Lessells R, Ogwell A E, Kebede Y, Tessema S
K and de Oliveira T 2022 Urgent need for a non-discriminatory and
non-stigmatizing nomenclature for monkeypox virus PLoS Biol 20 e3001769
[20] Anon 2022 Monkeypox: experts give virus variants new names
[21] Chen N, Li G, Liszewski M K, Atkinson J P, Jahrling P B, Feng
Z, Schriewer J, Buck C, Wang C, Lefkowitz E J, Esposito J J, Harms T,
Damon I K, Roper R L, Upton C and Buller R M L 2005 Virulence
differences between monkeypox virus isolates from West Africa and the
Congo basin Virology 340 46–63
[22] Parker S and Buller R M 2013 A review of experimental and
natural infections of animals with monkeypox virus between 1958 and 2012
Future Virol 8 129–57
[23] Bunge E M, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer L R
and Steffen R 2022 The changing epidemiology of human monkeypox—A
potential threat? A systematic review PLoS Negl Trop Dis 16 e0010141
[24] Lum F-M, Torres-Ruesta A, Tay M Z, Lin R T P, Lye D C, Rénia L
and Ng L F P 2022 Monkeypox: disease epidemiology, host immunity and
clinical interventions Nat Rev Immunol 22 597–613
[25] Swiss Institute of Bioinformatics (SIB) 2022 Orthopoxvirus
~ ViralZone
[26] Pickup D J 2015 Extracellular Virions: The Advance Guard of
Poxvirus Infections PLoS Pathog 11 e1004904
[27] Kmiec D and Kirchhoff F 2022 Monkeypox: A New Threat? Int J Mol
Sci 23 7866
[28] Smith G L, Vanderplasschen A and Law M 2002 The formation and
function of extracellular enveloped vaccinia virus J Gen Virol 83
2915–31
[29] Realegeno S, Priyamvada L, Kumar A, Blackburn J B, Hartloge C,
Puschnik A S, Sambhara S, Olson V A, Carette J E, Lupashin V and
Satheshkumar P S 2020 Conserved Oligomeric Golgi (COG) Complex Proteins
Facilitate Orthopoxvirus Entry, Fusion and Spread Viruses 12 707
[30] Realegeno S, Puschnik A S, Kumar A, Goldsmith C, Burgado J,
Sambhara S, Olson V A, Carroll D, Damon I, Hirata T, Kinoshita T,
Carette J E and Satheshkumar P S 2017 Monkeypox Virus Host Factor Screen
Using Haploid Cells Identifies Essential Role of GARP Complex in
Extracellular Virus Formation J Virol 91 e00011-17
[31] Lopera J G, Falendysz E A, Rocke T E and Osorio J E 2015
Attenuation of monkeypox virus by deletion of genomic regions Virology
475 129–38
[32] Yu H, Bruneau R C, Brennan G and Rothenburg S 2021 Battle
Royale: Innate Recognition of Poxviruses and Viral Immune Evasion
Biomedicines 9 765
[33] Bartlett N W, Dumoutier L, Renauld J-C, Kotenko S V, McVey C E,
Lee H-J and Smith G L 2004 A new member of the interleukin 10-related
cytokine family encoded by a poxvirus J Gen Virol 85 1401–12
[34] Wong P-S, Sutejo R, Chen H, Ng S-H, Sugrue R J and Tan B-H 2018
A System Based-Approach to Examine Cytokine Response in
Poxvirus-Infected Macrophages Viruses 10 692
[35] Lalani A S and McFadden G 1997 Secreted poxvirus chemokine
binding proteins J Leukoc Biol 62 570–6
[36] Meng X, Schoggins J, Rose L, Cao J, Ploss A, Rice C M and Xiang
Y 2012 C7L Family of Poxvirus Host Range Genes Inhibits Antiviral
Activities Induced by Type I Interferons and Interferon Regulatory
Factor 1 J Virol 86 4538–47
[37] Paust S, Senman B and von Andrian U H 2010 Adaptive immune
responses mediated by natural killer cells Immunol Rev 235 286–96
[38] Jahrling P B, Hensley L E, Martinez M J, LeDuc J W, Rubins K H,
Relman D A and Huggins J W 2004 Exploring the potential of variola virus
infection of cynomolgus macaques as a model for human smallpox Proc Natl
Acad Sci U S A 101 15196–200
[39] Song H, Josleyn N, Janosko K, Skinner J, Reeves R K, Cohen M,
Jett C, Johnson R, Blaney J E, Bollinger L, Jennings G and Jahrling P B
2013 Monkeypox virus infection of rhesus macaques induces massive
expansion of natural killer cells but suppresses natural killer cell
functions PLoS One 8 e77804
[40] Strassburg M A 1982 The global eradication of smallpox American
Journal of Infection Control 10 53–9
[41] Cherry J D, McIntosh K, Connor J D, Benenson A S, Alling D W,
Rolfe U T, Todd W A, Schanberger J E and Mattheis M J 1977 Primary
Percutaneous Vaccination The Journal of Infectious Diseases 135 145–54
[42] Keasey S, Pugh C, Tikhonov A, Chen G, Schweitzer B, Nalca A and
Ulrich R G 2010 Proteomic Basis of the Antibody Response to Monkeypox
Virus Infection Examined in Cynomolgus Macaques and a Comparison to
Human Smallpox Vaccination PLOS ONE 5 e15547
[43] MacLeod M K L, Clambey E T, Kappler J W and Marrack P 2009 CD4
memory T cells: what are they and what can they do? Semin Immunol 21
53–61
[44] Hickman H D, Reynoso G V, Ngudiankama B F, Rubin E J, Magadán J
G, Cush S S, Gibbs J, Molon B, Bronte V, Bennink J R and Yewdell J W
2013 Anatomically restricted synergistic antiviral activities of innate
and adaptive immune cells in the skin Cell Host Microbe 13 155–68
[45] Goulding J, Abboud G, Tahiliani V, Desai P, Hutchinson T and
Salek-Ardakani S 2014 CD8 T cells utilize IFN-γ to protect against the
lethal effects of a respiratory poxvirus infection J Immunol 192
5415–25
[46] Iwasaki A and Medzhitov R 2010 Regulation of adaptive immunity
by the innate immune system Science 327 291–5
[47] Kawai T and Akira S 2006 Innate immune recognition of viral
infection Nat Immunol 7 131–7
[48] Rathinam V A K and Fitzgerald K A 2011 Innate Immune sensing of
DNA viruses Virology 411 153–62
[49] O’Neill L A J and Bowie A G 2007 The family of five:
TIR-domain-containing adaptors in Toll-like receptor signalling Nat Rev
Immunol 7 353–64
[50] Shchelkunov S N 2012 Orthopoxvirus Genes That Mediate Disease
Virulence and Host Tropism Adv Virol 2012 524743
[51] Shi Y 2004 Caspase activation, inhibition, and reactivation: A
mechanistic view Protein Sci 13 1979–87
[52] Youle R J and Strasser A 2008 The BCL-2 protein family:
opposing activities that mediate cell death Nat Rev Mol Cell Biol 9
47–59
[53] Arndt W D, White S D, Johnson B P, Huynh T, Liao J, Harrington
H, Cotsmire S, Kibler K V, Langland J and Jacobs B L 2016 Monkeypox
virus induces the synthesis of less dsRNA than vaccinia virus, and is
more resistant to the anti-poxvirus drug, IBT, than vaccinia virus
Virology 497 125–35
[54] Arndt W D, Cotsmire S, Trainor K, Harrington H, Hauns K, Kibler
K V, Huynh T P and Jacobs B L 2015 Evasion of the Innate Immune Type I
Interferon System by Monkeypox Virus J Virol 89 10489–99
[55] Hudson P N, Self J, Weiss S, Braden Z, Xiao Y, Girgis N M,
Emerson G, Hughes C, Sammons S A, Isaacs S N, Damon I K and Olson V A
2012 Elucidating the Role of the Complement Control Protein in Monkeypox
Pathogenicity PLoS One 7 e35086
[56] Jezek Z, Szczeniowski M, Paluku K M and Mutombo M 1987 Human
monkeypox: clinical features of 282 patients J Infect Dis 156 293–8
[57] Petersen E, Kantele A, Koopmans M, Asogun D, Yinka-Ogunleye A,
Ihekweazu C and Zumla A 2019 Human Monkeypox Infect Dis Clin North Am 33
1027–43
[58] Adler H, Gould S, Hine P, Snell L B, Wong W, Houlihan C F,
Osborne J C, Rampling T, Beadsworth M B, Duncan C J, Dunning J, Fletcher
T E, Hunter E R, Jacobs M, Khoo S H, Newsholme W, Porter D, Porter R J,
Ratcliffe L, Schmid M L, Semple M G, Tunbridge A J, Wingfield T, Price N
M, and NHS England High Consequence Infectious Diseases (Airborne)
Network 2022 Clinical features and management of human monkeypox: a
retrospective observational study in the UK Lancet Infect Dis 22
1153–62
[59] Ogoina D, Iroezindu M, James H I, Oladokun R, Yinka-Ogunleye A,
Wakama P, Otike-Odibi B, Usman L M, Obazee E, Aruna O and Ihekweazu C
2020 Clinical Course and Outcome of Human Monkeypox in Nigeria Clin
Infect Dis 71 e210–4
[60] Hutson C L, Carroll D S, Gallardo-Romero N, Weiss S, Clemmons
C, Hughes C M, Salzer J S, Olson V A, Abel J, Karem K L and Damon I K
2011 Monkeypox disease transmission in an experimental setting: prairie
dog animal model PLoS One 6 e28295
[61] CDC 2022 Monkeypox in the U.S. Centers for Disease Control and
Prevention
[62] Vivancos R, Anderson C, Blomquist P, Balasegaram S, Bell A,
Bishop L, Brown C S, Chow Y, Edeghere O, Florence I, Logan S, Manley P,
Crowe W, McAuley A, Shankar A G, Mora-Peris B, Paranthaman K, Prochazka
M, Ryan C, Simons D, Vipond R, Byers C, Watkins N A, Welfare W,
Whittaker E, Dewsnap C, Wilson A, Young Y, Chand M, Riley S, Hopkins S,
Charlett A, Finnie T, McAuslane H, Weeple B, Fifer H, Sinka K, Edwards
D, Lopez-Bernal J, Rampling T, Lee A, Mellon D, Kliner M, Young N, Makki
S, Coles S, Shepherd W, Latham V, Tabor R, Graham A, Yuan J, MacDonald
N, Vusirikala A, Ma T, Cooper K and Saavedra-Campos M 2022 Community
transmission of monkeypox in the United Kingdom, April to May 2022 Euro
Surveill 27 2200422
[63] Philpott D, Hughes C M, Alroy K A, Kerins J L, Pavlick J, Asbel
L, Crawley A, Newman A P, Spencer H, Feldpausch A, Cogswell K, Davis K
R, Chen J, Henderson T, Murphy K, Barnes M, Hopkins B, Fill M-M A,
Mangla A T, Perella D, Barnes A, Hughes S, Griffith J, Berns A L, Milroy
L, Blake H, Sievers M M, Marzan-Rodriguez M, Tori M, Black S R, Kopping
E, Ruberto I, Maxted A, Sharma A, Tarter K, Jones S A, White B,
Chatelain R, Russo M, Gillani S, Bornstein E, White S L, Johnson S A,
Ortega E, Saathoff-Huber L, Syed A, Wills A, Anderson B J, Oster A M,
Christie A, McQuiston J, McCollum A M, Rao A K, Negrón M E, Griffin I,
Khan M, Ogale Y, Sims E, Lash R R, Rainey J J, Charniga K, Waltenburg M
A, Dawson P, Quilter L A S, Rushmore J, Stenger M R, Kachur R E,
Whitehill F, Jackson K A, Collins J, Signs K, Richardson G, Hand J,
Spence-Davizon E, Steidley B, Osborne M, Soliva S, Cook S, Ayuk-Takor L,
Willut C, Snively A, Lehnertz N, Quilliam D N, Durham M, Cardona-Gerena
I R, Bell L J, Control E, Kuljanin M, Gibbons-Burgener S, Westergaard R,
Sosa L E, Beddo M, Donahue M, Koirala S, Dewart C, Murray-Thompson J,
Peake L, Holshue M L, et al 2022 Epidemiologic and Clinical
Characteristics of Monkeypox Cases — United States, May 17–July 22,
2022 MMWR Morb Mortal Wkly Rep 71 1018–22
[64] Daskalakis D, McClung R P, Mena L, Mermin J, and Centers for
Disease Control and Prevention’s Monkeypox Response Team 2022 Monkeypox:
Avoiding the Mistakes of Past Infectious Disease Epidemics Ann Intern
Med 175 1177–8
[65] Commissioner O of the 2020 FDA approves first live,
non-replicating vaccine to prevent smallpox and monkeypox FDA
[66] Volz A and Sutter G 2017 Modified Vaccinia Virus Ankara Adv
Virus Res 97 187–243
[67] Yang G, Pevear D C, Davies M H, Collett M S, Bailey T, Rippen
S, Barone L, Burns C, Rhodes G, Tohan S, Huggins J W, Baker R O, Buller
R L M, Touchette E, Waller K, Schriewer J, Neyts J, DeClercq E, Jones K,
Hruby D and Jordan R 2005 An orally bioavailable antipoxvirus compound
(ST-246) inhibits extracellular virus formation and protects mice from
lethal orthopoxvirus Challenge J Virol 79 13139–49
[68] Russo A T, Berhanu A, Bigger C B, Prigge J, Silvera P M,
Grosenbach D W and Hruby D 2020 Co-administration of tecovirimat and
ACAM2000TM in non-human primates: Effect of tecovirimat treatment on
ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus
challenge Vaccine 38 644–54
[69] Anon Monkeypox Virus Infection in Humans across 16 Countries
— April–June 2022 | NEJM
[70] Anon FDA Mpox Response | FDA
[71] Russo A T, Grosenbach D W, Chinsangaram J, Honeychurch K M,
Long P G, Lovejoy C, Maiti B, Meara I and Hruby D E 2021 An overview of
tecovirimat for smallpox treatment and expanded anti-orthopoxvirus
applications Expert Review of Anti-infective Therapy 19 331–44
[72] Ali Y, Imtiaz H, Tahir M M, Gul F, Saddozai U A K, ur Rehman A,
Ren Z-G, Khattak S and Ji X-Y 2023 Fragment-Based Approaches Identified
Tecovirimat-Competitive Novel Drug Candidate for Targeting the F13
Protein of the Monkeypox Virus Viruses 15 570
[73] Chen Z-R, Lv Q-L, Peng H-W, Liu X-Y, Hu W-L and Hu J-F 2022
Drug screening against F13 protein, the target of tecovirimat, as
potential therapies for monkeypox virus J Infect
[74] Andrei G and Snoeck R 2010 Cidofovir Activity against Poxvirus
Infections Viruses 2 2803–30
[75] Meyer H, Ehmann R and Smith G L 2020 Smallpox in the
Post-Eradication Era Viruses 12 138
[76] Jezek Z, Marennikova S S, Mutumbo M, Nakano J H, Paluku K M and
Szczeniowski M 1986 Human monkeypox: a study of 2,510 contacts of 214
patients J Infect Dis 154 551–5